Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Receives $36.50 Consensus Price Target from Analysts

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) have earned a consensus rating of “Hold” from the eight analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $36.50.

Several analysts recently commented on the company. Weiss Ratings restated a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, May 26th. Wall Street Zen cut Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Zacks Research upgraded Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th.

Lakefront Biotherapeutics American Depositary Shares Price Performance

LKFT stock opened at $29.48 on Monday. The company has a 50 day simple moving average of $28.18 and a 200 day simple moving average of $30.97. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -20.91 and a beta of 0.26. Lakefront Biotherapeutics American Depositary Shares has a 1 year low of $26.42 and a 1 year high of $37.78.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its quarterly earnings data on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share (EPS) for the quarter. The firm had revenue of $1.06 billion during the quarter. On average, equities research analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

A number of large investors have recently modified their holdings of the company. Madison Avenue Partners LP lifted its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 0.8% in the 4th quarter. Madison Avenue Partners LP now owns 2,213,169 shares of the biotechnology company’s stock worth $72,371,000 after purchasing an additional 17,394 shares in the last quarter. Ameriprise Financial Inc. raised its position in Lakefront Biotherapeutics American Depositary Shares by 2,490.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,416,934 shares of the biotechnology company’s stock valued at $49,083,000 after buying an additional 1,362,229 shares during the last quarter. UBS Group AG raised its position in Lakefront Biotherapeutics American Depositary Shares by 128.4% in the 4th quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock valued at $11,427,000 after buying an additional 196,445 shares during the last quarter. Millennium Management LLC raised its position in Lakefront Biotherapeutics American Depositary Shares by 121.9% in the 4th quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock valued at $11,097,000 after buying an additional 186,452 shares during the last quarter. Finally, Jane Street Group LLC raised its position in Lakefront Biotherapeutics American Depositary Shares by 2,245.7% in the 1st quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock valued at $2,783,000 after buying an additional 115,946 shares during the last quarter. 32.46% of the stock is currently owned by institutional investors.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.